GC-targeted C8-linked pyrrolobenzodiazepine-biaryl conjugates with femtomolar in vitro cytotoxicity and in vivo antitumor activity in mouse models.
|Title||GC-targeted C8-linked pyrrolobenzodiazepine-biaryl conjugates with femtomolar in vitro cytotoxicity and in vivo antitumor activity in mouse models.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Rahman KM, Jackson PJM, James CH, B Basu P, Hartley JA, de la Fuente M, Schätzlein A, Robson M, R Pedley B, Pepper C, Fox KR, Howard PW, Thurston DE|
|Journal||J Med Chem|
|Date Published||2013 Apr 11|
|Keywords||Animals, Antineoplastic Agents, Benzodiazepines, Cell Line, Tumor, Disease Models, Animal, Drug Screening Assays, Antitumor, Fluorescence Resonance Energy Transfer, GC Rich Sequence, Humans, In Vitro Techniques, Magnetic Resonance Spectroscopy, Mice, Models, Molecular, Molecular Structure, NF-kappa B, Spectrometry, Mass, Electrospray Ionization|
DNA binding 4-(1-methyl-1H-pyrrol-3-yl)benzenamine (MPB) building blocks have been developed that span two DNA base pairs with a strong preference for GC-rich DNA. They have been conjugated to a pyrrolo[2,1-c][1,4]benzodiazepine (PBD) molecule to produce C8-linked PBD-MPB hybrids that can stabilize GC-rich DNA by up to 13-fold compared to AT-rich DNA. Some have subpicomolar IC50 values in human tumor cell lines and in primary chronic lymphocytic leukemia cells, while being up to 6 orders less cytotoxic in the non-tumor cell line WI38, suggesting that key DNA sequences may be relevant targets in these ultrasensitive cancer cell lines. One conjugate, 7h (KMR-28-39), which has femtomolar activity in the breast cancer cell line MDA-MB-231, has significant dose-dependent antitumor activity in MDA-MB-231 (breast) and MIA PaCa-2 (pancreatic) human tumor xenograft mouse models with insignificant toxicity at therapeutic doses. Preliminary studies suggest that 7h may sterically inhibit interaction of the transcription factor NF-κB with its cognate DNA binding sequence.
|Alternate Journal||J. Med. Chem.|
|Grant List||C180/A1060 / / Cancer Research UK / United Kingdom|